SABS Stock Overview
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
SAB Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.40 |
| 52 Week High | US$11.90 |
| 52 Week Low | US$4.00 |
| Beta | 0.80 |
| 1 Month Change | 3.53% |
| 3 Month Change | -26.67% |
| 1 Year Change | -39.02% |
| 3 Year Change | -95.56% |
| 5 Year Change | n/a |
| Change since IPO | -95.67% |
Recent News & Updates
Recent updates
Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified
Apr 17
Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week
Jan 20Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues
Nov 19Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 18SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial
Sep 28What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates
Aug 12SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03
Aug 10Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term
Apr 06SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies
Dec 02Shareholder Returns
| SABS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.3% | 1.0% | 1.2% |
| 1Y | -39.0% | 0.7% | 24.9% |
Return vs Industry: SABS underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: SABS underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| SABS volatility | |
|---|---|
| SABS Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SABS's share price has been volatile over the past 3 months.
Volatility Over Time: SABS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 57 | Samuel Reich | www.sabbiotherapeutics.com |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma.
SAB Biotherapeutics, Inc. Fundamentals Summary
| SABS fundamental statistics | |
|---|---|
| Market cap | US$40.22m |
| Earnings (TTM) | -US$42.19m |
| Revenue (TTM) | US$2.24m |
18.1x
P/S Ratio-1.0x
P/E RatioIs SABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SABS income statement (TTM) | |
|---|---|
| Revenue | US$2.24m |
| Cost of Revenue | US$619.49k |
| Gross Profit | US$1.62m |
| Other Expenses | US$43.81m |
| Earnings | -US$42.19m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.57 |
| Gross Margin | 72.33% |
| Net Profit Margin | -1,884.50% |
| Debt/Equity Ratio | 1.8% |
How did SABS perform over the long term?
See historical performance and comparison